Catalent Pharma Solutions appoints Chief technology officer to lead innovation activities

Catalent Pharma Solutions, Inc. announced today the appointment of Kurt Nielsen, Ph.D. as Chief Technology Officer and Senior Vice President, Innovation and Growth, effective immediately.

This content was submitted directly to this website by the supplier.

Dr. Nielsen will have responsibility for driving innovation activities and investments across Catalent's broad range of advanced dose forms and packaging technologies. Dr. Nielsen will report to John Chiminski, President and CEO of Catalent, and will be based in Catalent's global headquarters in Somerset, New Jersey.

Dr. Nielsen most recently served as Executive Vice President of Pharmaceuticals for URLMutual Pharmaceutical Company, where he lead new product development and licensing activities for both products and drug delivery technologies, as well as the division's manufacturing and quality operations. He had previously held the position of Vice President, Research and Development at URLMutual. Dr. Nielsen also held prior research and development leadership positions with Teva Pharmaceuticals USA and the McNeil Consumer Products division of Johnson & Johnson. Dr. Nielsen holds a Ph.D. in Chemistry from Villanova University, and a Bachelor of Science in Chemistry from the University of Delaware.

John Chiminski, Catalent's President and CEO, said, “We are excited to have Kurt join the Catalent executive team. Catalent's foundation was built on proprietary technologies, and Kurt's experience and leadership will accelerate and deepen our innovation activities for existing and new platforms. With his deep background in both pharmaceutical sciences and commercial activities, Kurt is uniquely suited to ensure we align our more than 1,000 scientists and engineers to produce the new innovations that both our customers and their patients need.”
Companies in this article
More in Home